脂质体布比卡因用于烧伤患者供皮区术后镇痛的前瞻性分析
本研究为观察性病例对照研究,纳入烧伤面积小于20%TBSA的成年患者,在下肢供皮区取皮后使用脂质体布比卡因镇痛,并与历史对照匹配比较。结果显示干预组术后第一天累积疼痛评分AUC0-24显著更低,住院时间更短,且未观察到与药物或阿片类药物相关的不良事件增加。
要点
- 脂质体布比卡因可降低烧伤供皮区术后24小时累积疼痛评分。
- 使用脂质体布比卡因与更短的住院时间相关。
- 未观察到与脂质体布比卡因或阿片类药物相关的不良事件增加。
核心结论
- 脂质体布比卡因用于烧伤患者供皮区术后镇痛安全有效,可降低术后24小时累积疼痛评分并缩短住院时间。
研究设计与样本
- 观察性病例对照研究,纳入烧伤面积小于20%TBSA的成年患者,干预组36例接受脂质体布比卡因,其中21例符合条件与历史对照匹配。
主要发现
- 干预组术后第一天累积疼痛评分AUC0-24中位数(IQR)为578(408,740),显著低于对照组的680(544,803),p=0.05。
- 干预组住院时间中位数(IQR)为4天(1,9.5),显著短于对照组的6天(3,18),p=0.01。
- 未观察到与脂质体布比卡因给药相关的不良事件或阿片类药物相关不良事件存在差异。
临床怎么用
- 对于烧伤面积小于20%TBSA的成年患者,下肢供皮区取皮术后可考虑使用脂质体布比卡因进行术后镇痛,以降低早期疼痛评分并可能缩短住院时间。
局限性
- 本研究为观察性病例对照研究,样本量有限,且部分患者未能匹配,结果需进一步随机对照研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Burn patients frequently require autograft harvesting to facilitate wound healing, often resulting in significant pain. Liposomal bupivacaine is indicated for administration into a surgical site to produce postsurgical analgesia. The objective of this study was to evaluate efficacy, safety, and duration of postoperative analgesia with liposomal bupivacaine for donor site pain in burn patients. This was an observational, case-control study including adult patients with <20% total body surface area (TBSA) burned who received liposomal bupivacaine for postoperative pain management after autograft harvesting from lower extremity donor site(s). Patients from the case group were matched to historical control patients treated with traditional pain management. The primary outcome was the cumulative pain scores on postoperative day one measured by the area under the curve (AUC0-24). Secondary outcomes included AUC0-72, total milligram morphine equivalents (MME), length of stay, and adverse events. Data were collected in 36 patients who received liposomal bupivacaine, with 21 patients eligible for matching to historical controls. Patients included in the intervention and control groups were well-matched at baseline. Patients in the intervention group had a significantly lower median (IQR) AUC0-24 [578 (408,740) vs. 680 (544,803); p = 0.05] and shorter length of stay [4 days (1,9.5) vs. 6 days (318); p = 0.01]. No differences in adverse events related to the administration of liposomal bupivacaine or opioid-related adverse events were observed. Results indicate liposomal bupivacaine is safe and effective in burn patients. The results of this study add to the limited body of literature examining efficacy in this population.
引用
- Boyd AN, Blair ME, Degenkolb KE, et al. A prospective analysis describing the innovative use of liposomal bupivacaine in burn patients. Burns. 2019. PMID: 31420265. doi:10.1016/j.burns.2019.07.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。